Melexis NV (LON:0FA0)
56.75
-2.00 (-3.40%)
At close: Dec 12, 2025
Melexis NV Revenue
Melexis NV had revenue of 215.29M EUR in the quarter ending September 30, 2025, a decrease of -13.14%. This brings the company's revenue in the last twelve months to 822.53M, down -16.57% year-over-year. In the year 2024, Melexis NV had annual revenue of 932.81M, down -3.27%.
Revenue (ttm)
822.53M EUR
Revenue Growth
-16.57%
P/S Ratio
2.83
Revenue / Employee
412.30K EUR
Employees
1,995
Market Cap
2.03B GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 932.81M | -31.49M | -3.27% |
| Dec 31, 2023 | 964.30M | 128.14M | 15.32% |
| Dec 31, 2022 | 836.16M | 192.37M | 29.88% |
| Dec 31, 2021 | 643.79M | 136.27M | 26.85% |
| Dec 31, 2020 | 507.52M | 20.66M | 4.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |